Tadalafil Tablet
Product Images NDC 68788-8664

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68788-8664). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure diagram of the active ingredient tadalafil displaying its molecular framework with labeled atoms and functional groups.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This image contains four line graphs showing the difference in blood pressure measurements (Tadalafil minus placebo) over time in hours. The charts display standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP variations following tadalafil administration compared to placebo, including error bars for variability.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs showing changes in systolic blood pressure over 24 hours post-dose. The top graph displays standing systolic blood pressure, and the bottom graph shows supine systolic blood pressure. Data compare Tadalafil 20 mg combined with doxazosin 8 mg (solid line) versus placebo with doxazosin 8 mg (dotted line). The x-axis represents time post-dose in hours, and the y-axis represents systolic blood pressure change in mmHg.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo with doxazosin. The x-axis represents time after administration in hours, and the y-axis represents systolic blood pressure changes. Four lines compare 20 mg tadalafil at 08:00 and 20:00 with placebo, both combined with 8 mg doxazosin at 08:00.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for single 20-mg, single 5-mg, and once-daily 5-mg doses following 5 consecutive days of administration. The graph includes error bars representing variability at each time point.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg tablets and placebo. The graph shows greater reduction in IPSS score with tadalafil compared to placebo at weeks 4, 8, and 12, with a statistically significant difference at week 12 (p<0.01).*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks for tadalafil 5 mg tablets versus placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change in score. Tadalafil shows a greater decrease in score compared to placebo, with statistical significance indicated at week 4 and week 12.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph titled 'Weeks of Therapy' showing least-squares mean change from baseline over 26 weeks for two groups: Tadalafil/Finasteride (diamond markers) and Placebo/Finasteride (circle markers). The graph includes statistical significance annotations (a p<0.001, b p<0.05) and indicates treatment differences at multiple time points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between tadalafil tablets 5 mg and placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change from baseline score. The tadalafil group shows a greater decrease in score compared to placebo throughout the study period, with statistical significance indicated at 12 weeks.*

FDA Label Image

Tadalafil Tablets 20mg (F35596a7 Figure 13)

Tadalafil Tablets 20 mg oral tablets packaging label from Preferred Pharmaceuticals, Inc. The label includes drug name, strength, generic indication as generic for Cialis, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd., and storage instructions. It features dosage directions in English and Spanish on a yellow background, caution statement about transfer restrictions, and spaces for quantity, lot, batch, and NDC information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.